Kura Oncology
KURA | NASDAQ
$7.09
-$0.68 (-8.75%)
At close: Nov 16, 2026, 4:00 PM ET
$7.35
+$0.26 (+3.67%)
After-hours:
Nov 16, 2026, 7:57 PM ET
Kura Oncology Company Profile
Company profile explainedCompany Profile
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Key Executives
| Name | Position |
|---|---|
| Troy Edward Wilson | Chairman, Chief Executive Officer & President |
| Jennifer Fulk | Chief Financial Officer |
| Kathleen Ford | Chief Operating Officer |
| Teresa Brophy Bair | Chief Legal Officer & Corporate Secretary |
| Brian T. Powl | Chief Commercial Officer |
| Francis J. Burrows | Chief Scientific Officer |
| Greg Mann | Senior Vice President of Investor Relations & Corporate Affairs |
| Mollie Leoni | Chief Medical Officer |
| Roger Bakale | Senior Vice President of Manufacturing & Supply Chain |
| Samir Vattompadam | Senior Vice President of Global Program Leadership |
| Thomas Doyle | Senior Vice President of Finance & Accounting |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 27, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Sep 29, 2026 | 4 | Filing |
| Sep 29, 2026 | 4 | Filing |
| Sep 29, 2026 | 4 | Filing |
| Sep 29, 2026 | 4 | Filing |
| Sep 29, 2026 | 4 | Filing |
| Sep 25, 2026 | 4 | Filing |
| Sep 10, 2026 | 4 | Filing |
| Sep 10, 2026 | 3 | Filing |
| Sep 09, 2026 | 8-K | Current Report |
Kura Oncology
| Country | United States |
| IPO Date | Sep 16, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 260 |
| CEO | Troy Wilson |
Contact Details
4930 Directors Place San Diego,
California 92121 United States
Stock Details
| Ticker Symbol | KURA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001422143 |
| CUSIP Number | 50127T109 |
| ISIN Number | US50127T1097 |
| SIC Code | 2834 |
Recent News
- 2 months ago / seekingalpha.comKura Oncology, Inc. (KURA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 2 months ago / globenewswire.comKura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes
- 2 months ago / globenewswire.comKura Oncology Appoints Jennifer Fulk as Chief Financial Officer
- 3 months ago / zacks.comKURA Stock Gains 37.6% in a Month: Here's What You Need to Know
- 3 months ago / globenewswire.comKura Oncology to Participate in Three Investor Conferences in September
- 3 months ago / zacks.comKura Oncology (KURA) Upgraded to Buy: What Does It Mean for the Stock?
- 3 months ago / seekingalpha.comKura Oncology: 'Strong Buy': Ziftomenib AML Expansions With Different Regimens Could Boost KOMZIFTI's Prospects
- 3 months ago / fool.comKura Oncology CEO Buys 100,000 Shares for $1.2 Million. Does This Large Buy Bode Well for Shares in 2026?
- 3 months ago / zacks.comKura Oncology (KURA) is a Great Momentum Stock: Should You Buy?
- 3 months ago / zacks.comDoes Kura Oncology (KURA) Have the Potential to Rally 178.55% as Wall Street Analysts Expect?
Add to Watchlist
Select watchlists to add or remove KURA